MX385085B - Uso de beta-agonistas del receptor de la hormona tiroidea. - Google Patents
Uso de beta-agonistas del receptor de la hormona tiroidea.Info
- Publication number
- MX385085B MX385085B MX2018012900A MX2018012900A MX385085B MX 385085 B MX385085 B MX 385085B MX 2018012900 A MX2018012900 A MX 2018012900A MX 2018012900 A MX2018012900 A MX 2018012900A MX 385085 B MX385085 B MX 385085B
- Authority
- MX
- Mexico
- Prior art keywords
- agonists
- hormone receptor
- thyroid hormone
- receptor beta
- beta
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326436P | 2016-04-22 | 2016-04-22 | |
| PCT/US2017/029120 WO2017185087A1 (en) | 2016-04-22 | 2017-04-24 | Use of thyroid beta-agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018012900A MX2018012900A (es) | 2019-07-01 |
| MX385085B true MX385085B (es) | 2025-03-14 |
Family
ID=60116400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012900A MX385085B (es) | 2016-04-22 | 2017-04-24 | Uso de beta-agonistas del receptor de la hormona tiroidea. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11351183B2 (https=) |
| EP (1) | EP3445373B1 (https=) |
| JP (1) | JP6931042B2 (https=) |
| KR (1) | KR102407059B1 (https=) |
| AU (1) | AU2017252126B2 (https=) |
| BR (1) | BR112018071586A2 (https=) |
| CA (1) | CA3021681C (https=) |
| ES (1) | ES2992773T3 (https=) |
| MX (1) | MX385085B (https=) |
| WO (1) | WO2017185087A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017252126B2 (en) | 2016-04-22 | 2023-02-09 | Metabasis Therapeutics, Inc. | Use of thyroid beta-agonists |
| ES3053674T3 (en) * | 2018-03-22 | 2026-01-23 | Viking Therapeutics Inc | Crystalline forms and methods of producing crystalline forms of a compound |
| WO2020117962A1 (en) | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| US11752161B2 (en) | 2020-03-27 | 2023-09-12 | Gannex Pharma Co., Ltd. | Pharmaceutical compositions, method of making and method of using thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| CA2543132A1 (en) | 2003-10-23 | 2005-05-19 | Celgene Corporation | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| CN1882327A (zh) | 2003-11-19 | 2006-12-20 | 症变治疗公司 | 含磷的新的拟甲状腺素药 |
| CA2584845C (en) | 2004-12-08 | 2009-02-17 | Sirion Therapeutics, Inc. | Methods, assays and compositions for treating retinol-related diseases |
| WO2006128056A2 (en) * | 2005-05-26 | 2006-11-30 | Metabasis Therapeutics, Inc. | Novel phosphinic acid-containing thyromimetics |
| MX2007014502A (es) | 2005-05-26 | 2008-02-07 | Metabasis Therapeutics Inc | Tiromimeticos para el tratamiento de enfermedades del higado graso. |
| US20090042857A1 (en) | 2006-02-20 | 2009-02-12 | Masuo Yamaoka | Novel Pharmaceutical |
| US20110071208A1 (en) | 2009-06-05 | 2011-03-24 | Protiva Biotherapeutics, Inc. | Lipid encapsulated dicer-substrate interfering rna |
| WO2011038207A1 (en) * | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| MX390699B (es) | 2011-06-21 | 2025-03-21 | Alnylam Pharmaceuticals Inc | Composiciones y metodos para inhibicion de genes para apolipoproteina c-iii (apoc3). |
| WO2014178892A1 (en) * | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
| PE20180021A1 (es) | 2015-02-20 | 2018-01-09 | Univ Oregon Health & Science | Derivados de sobetiroma |
| RU2719245C2 (ru) | 2016-02-29 | 2020-04-17 | Филип Моррис Продактс С.А. | Тара и заготовка с шарнирной крышкой |
| AU2017252126B2 (en) | 2016-04-22 | 2023-02-09 | Metabasis Therapeutics, Inc. | Use of thyroid beta-agonists |
| BR112018071559B1 (pt) | 2016-04-22 | 2024-02-06 | Viking Therapeutics, Inc | Uso de um agonista de receptor beta de hormônios da tireoide para o tratamento de adrenoleucodistrofia ligada ao x |
| DK3457851T3 (da) | 2016-05-18 | 2021-09-20 | Univ Oregon Health & Science | Derivater af sobetirom |
-
2017
- 2017-04-24 AU AU2017252126A patent/AU2017252126B2/en active Active
- 2017-04-24 KR KR1020187033713A patent/KR102407059B1/ko active Active
- 2017-04-24 WO PCT/US2017/029120 patent/WO2017185087A1/en not_active Ceased
- 2017-04-24 EP EP17786798.3A patent/EP3445373B1/en active Active
- 2017-04-24 BR BR112018071586-7A patent/BR112018071586A2/pt not_active Application Discontinuation
- 2017-04-24 CA CA3021681A patent/CA3021681C/en active Active
- 2017-04-24 US US16/095,228 patent/US11351183B2/en active Active
- 2017-04-24 ES ES17786798T patent/ES2992773T3/es active Active
- 2017-04-24 MX MX2018012900A patent/MX385085B/es unknown
- 2017-04-24 JP JP2019507069A patent/JP6931042B2/ja active Active
-
2022
- 2022-05-06 US US17/738,621 patent/US11951114B2/en active Active
-
2024
- 2024-03-05 US US18/595,919 patent/US12440502B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190321379A1 (en) | 2019-10-24 |
| MX2018012900A (es) | 2019-07-01 |
| EP3445373A1 (en) | 2019-02-27 |
| KR20190039027A (ko) | 2019-04-10 |
| ES2992773T3 (en) | 2024-12-18 |
| AU2017252126A1 (en) | 2018-11-08 |
| US20220257618A1 (en) | 2022-08-18 |
| US11351183B2 (en) | 2022-06-07 |
| US12440502B2 (en) | 2025-10-14 |
| KR102407059B1 (ko) | 2022-06-10 |
| WO2017185087A1 (en) | 2017-10-26 |
| BR112018071586A2 (pt) | 2019-02-12 |
| EP3445373A4 (en) | 2019-12-18 |
| CA3021681A1 (en) | 2017-10-26 |
| AU2017252126B2 (en) | 2023-02-09 |
| US20250000880A1 (en) | 2025-01-02 |
| CA3021681C (en) | 2024-09-24 |
| EP3445373B1 (en) | 2024-08-21 |
| JP2019515033A (ja) | 2019-06-06 |
| JP6931042B2 (ja) | 2021-09-01 |
| US11951114B2 (en) | 2024-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17063327A (es) | Receptores de antígeno quiméricos antidll3 y métodos de uso | |
| MX374788B (es) | Anticuerpos anti-tim3 y metodos de uso. | |
| MX386587B (es) | ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO. | |
| ECSP17031725A (es) | Receptores quiméricos de anitígeno anti-clon y métodos de uso | |
| CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
| CL2017000590A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
| EA201791117A1 (ru) | Частичные агонисты инсулинового рецептора | |
| EA201790545A1 (ru) | Антитела и иммуноконъюгаты против her2 | |
| CL2017001289A1 (es) | Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr). | |
| MX372675B (es) | Anticuerpos anti-jagged1 y metodos de uso. | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| MY195115A (en) | Antibodies targeting g-protein coupled receptor and methods of use | |
| MX376026B (es) | Inmunoreceptores especificos de claudina-6 y epitopos de celulas t. | |
| LT3183268T (lt) | Anti-cd123 chimerinis antigeno receptorius (car), skirtas naudoti vėžio gydymui | |
| ES2796903T8 (es) | Procedimiento de uso de inmunoconjugados anti-CD79b | |
| CO2017002159A2 (es) | Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
| MX384989B (es) | Uso de un agonista del receptor x retinoide (rxr) en combinación con una hormona tiroidea para el tratamiento de esclerosis múltiple. | |
| CL2018003045A1 (es) | Semaglutida en afecciones cardiovasculares. | |
| MX384037B (es) | Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso. | |
| MX2018007818A (es) | Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso. | |
| MX385085B (es) | Uso de beta-agonistas del receptor de la hormona tiroidea. | |
| EA201790373A1 (ru) | Способы получения модуляторов toll-подобных рецепторов | |
| EA201792312A1 (ru) | Конструкции на основе калихеамицина и способы их применения | |
| MX2018012904A (es) | Uso de beta-agonistas del receptor de la hormona tiroidea. | |
| CR20140051A (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida |